JJ&K Pharma LTD
Your Global Partner in Life-Saving Medications
Company Profile
|
|
State-of-the-art pharmaceutical manufacturing
With over 30 years of industry experience, our core business sectors are heparin-series anticoagulation Finished Dosage Forms as well as Active Pharmaceutical Ingredients. Our complete product range includes anti-diabetic, respiratory, and oncology medications, and continues to expand to support our customers' needs. We are active in numerous markets around the world, including Europe, USA, the Middle East, Africa, India, and Southeast Asia. |
|
The heparins expert
We are the leading manufacturer of heparin-series products in Chongqing, China. We are also one of the largest facilities capable of full supply chain integration starting directly from the source material: From intestine collection and mucosa extraction, to active pharmaceutical ingredients and finished dosage forms, all manufacturing activities are carried out within our facilities and subject to rigorous quality controls at every stage. By ensuring the quality and accessibility of our products, we are committed to providing reliable pharmaceutical products and stellar customer satisfaction. Our manufacturing sites total nearly 25 hectares of land and have an annual capacity of 100 million ampoules, 50 million pre-filled syringes and 50 million vials of various strength heparins injectables. As we continue to grow, this capacity is scheduled to triple within the next 5 years.
Our main heparin-series products are available as FDF injectables as well as API:
|
|
Manufacturing Sites
|
Yubei API site The first plant, completed in 2015, produces fractionated and unfractionated heparin-series Active Pharmaceutical Ingredients. It currently holds EU-GMP for Heparin Sodium, Heparin Calcium, Enoxaparin, Nadroparin, and Dalteparin production, in addition to the Drug Manufacturing License issued by the Chinese NMPA.
|
Kaizhou FDF site The second plant covers an area of 22.8 hectares and specializes in Finished Dosage Forms for anticoagulation, anti-diabetic, and other drugs. Phase 1 construction will complete by the end of 2024, with pilot production beginning in Q4. GMP inspections by multiple authorities are scheduled for 2025 Q3.
|
In order to get where we are now has certainly been a long journey. And this is just the beginning.
QUALITY
With applications in major surgeries and life-critical conditions, ensuring the quality and efficacy of our products is paramount to safeguarding patient health.
From raw material sourcing to final product distribution, our rigorous quality management system ensures that every product meets stringent regulatory standards. Each batch at every stage of production is analyzed and documented by experienced production and quality engineers who undergo regular GMP training.
Through our unwavering dedication to quality, we aim to enhance the well-being of patients worldwide.
INNOVATION
Our R&D team is composed of innovative and highly skilled professionals dedicated to advancing our product offerings. They are constantly exploring new technologies, methodologies, and scientific discoveries to drive innovation and maintain our competitive edge. Their expertise spans multiple disciplines, allowing for a comprehensive approach to research and development.
Through rigorous testing and continuous improvement, our team ensures that our solutions meet the highest standards of quality and efficacy
